NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 309 filers reported holding NOVOCURE LTD in Q1 2022. The put-call ratio across all filers is 1.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,427,402 | -43.5% | 82,588 | -18.1% | 0.19% | -47.3% |
| Q1 2023 | $6,063,736 | -3.7% | 100,827 | +17.4% | 0.36% | -16.1% |
| Q4 2022 | $6,296,951 | -4.6% | 85,848 | -1.2% | 0.43% | -5.7% |
| Q3 2022 | $6,603,000 | +3.0% | 86,903 | -5.8% | 0.46% | -4.6% |
| Q2 2022 | $6,410,000 | -27.6% | 92,232 | -13.7% | 0.48% | -4.6% |
| Q1 2022 | $8,857,000 | +19.7% | 106,902 | +8.5% | 0.50% | +34.3% |
| Q4 2021 | $7,398,000 | -25.9% | 98,540 | +14.7% | 0.38% | -30.8% |
| Q3 2021 | $9,981,000 | -45.2% | 85,916 | +4.6% | 0.54% | -45.9% |
| Q2 2021 | $18,212,000 | +122.8% | 82,101 | +32.8% | 1.00% | +103.4% |
| Q1 2021 | $8,173,000 | -20.8% | 61,829 | +3.7% | 0.49% | -18.1% |
| Q4 2020 | $10,316,000 | +57.6% | 59,618 | +1.4% | 0.60% | +35.9% |
| Q3 2020 | $6,544,000 | +320.8% | 58,794 | +124.2% | 0.44% | +203.4% |
| Q2 2020 | $1,555,000 | -11.9% | 26,222 | 0.0% | 0.15% | -26.3% |
| Q1 2020 | $1,766,000 | – | 26,222 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |